BRD4-mediated repression of p53 is a target for combination therapy in AML

Acute myeloid leukemia (AML) is a typically lethal molecularly heterogeneous disease, with few broad-spectrum therapeutic targets. Unusually, most AML retain wild-type TP53, encoding the pro-apoptotic tumor suppressor p53. MDM2 inhibitors (MDM2i), which activate wild-type p53, and BET inhibitors (BE...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Nat Commun
Autors principals: Latif, Anne-Louise, Newcombe, Ashley, Li, Sha, Gilroy, Kathryn, Robertson, Neil A., Lei, Xue, Stewart, Helen J. S., Cole, John, Terradas, Maria Terradas, Rishi, Loveena, McGarry, Lynn, McKeeve, Claire, Reid, Claire, Clark, William, Campos, Joana, Kirschner, Kristina, Davis, Andrew, Lopez, Jonathan, Sakamaki, Jun-ichi, Morton, Jennifer P., Ryan, Kevin M., Tait, Stephen W. G., Abraham, Sheela A., Holyoake, Tessa, Higgins, Brian, Huang, Xu, Blyth, Karen, Copland, Mhairi, Chevassut, Timothy J. T., Keeshan, Karen, Adams, Peter D.
Format: Artigo
Idioma:Inglês
Publicat: Nature Publishing Group UK 2021
Matèries:
Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC7801601/
https://ncbi.nlm.nih.gov/pubmed/33431824
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/s41467-020-20378-8
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars